tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: AVEO Pharma (AVEO), MannKind (MNKD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AVEO Pharma (AVEOResearch Report), MannKind (MNKDResearch Report) and Ultragenyx Pharmaceutical (RAREResearch Report) with bullish sentiments.

AVEO Pharma (AVEO)

In a report released yesterday, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on AVEO Pharma, with a price target of $17.00. The company’s shares closed last Wednesday at $4.15.

According to TipRanks.com, Kusy is ranked 0 out of 5 stars with an average return of -41.1% and a 9.9% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Karyopharm Therapeutics, and Apellis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AVEO Pharma with a $15.75 average price target, a 279.5% upside from current levels. In a report issued on May 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $19.00 price target.

See today’s best-performing stocks on TipRanks >>

MannKind (MNKD)

In a report issued on May 17, Thomas Smith from SVB Securities reiterated a Buy rating on MannKind. The company’s shares closed last Wednesday at $3.19.

According to TipRanks.com, Smith ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -28.6% and a 17.3% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Prometheus Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MannKind with a $6.33 average price target.

Ultragenyx Pharmaceutical (RARE)

SVB Securities analyst Joseph Schwartz reiterated a Buy rating on Ultragenyx Pharmaceutical on May 17. The company’s shares closed last Wednesday at $47.70.

According to TipRanks.com, Schwartz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.8% and a 26.3% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Mereo Biopharma Group Plc, and Crinetics Pharmaceuticals.

Ultragenyx Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $113.13, which is an 114.9% upside from current levels. In a report issued on May 6, Cowen & Co. also maintained a Buy rating on the stock with a $99.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AVEO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed